GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (STU:1UC) » Definitions » Net Interest Income (for Banks)

Cue Biopharma (STU:1UC) Net Interest Income (for Banks)


View and export this data going back to 2023. Start your Free Trial

What is Cue Biopharma Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Cue Biopharma (STU:1UC) Business Description

Industry
Traded in Other Exchanges
Address
40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.